In the Texas Medication Algorithm Project (TMAP), patients were given algorithm-guided treatment (ALGO) or treatment as usual (TAU). The ALGO intervention included a clinical coordinator to assist the physicians and administer a patient and family education program. The primary comparison in the schizophrenia module of TMAP was between patients seen in clinics in which ALGO was used (n = 165) and patients seen in clinics in which no algorithms were used (n = 144). A third group of patients, seen in clinics using an algorithm for bipolar or major depressive disorder but not for schizophrenia, was also studied (n = 156). The ALGO group had modestly greater improvement in symptoms (Brief Psychiatric Rating Scale) during the first quarter of treatment The TAU group caught up by the end of 12 months. Cognitive functions were more improved in ALGO than in TAU at 3 months, and this difference was greater at 9 months (the final cognitive assessment). In secondary comparisons of ALGO with the second TAU group, the greater improvement in cognitive functioning was again noted, but the initial symptom difference was not significant
A number of studies have found that the use of medications in outpatients with schizophrenia frequently does not conform to expert recommendations (Lehman and Steinwachs 1998; Buchanan et al. 2002) and is often suboptimal or poorly documented (Young et al. 1998; Cradock et al. 2001) . These findings have given added impetus to efforts to develop medication guidelines and algorithms, based on the premise that they will reduce variability in medication practices, improve quality of care, and lead to better patient outcomes. Considerable evidence, however, indicates that, in the absence of specific measures to promote physician adherence to the guideline or algorithm, actual practice behaviors are little affected by the adoption of guidelines or algorithms by behavioral health care organizations (see literature reviews in Gilbert et al. 1998; Bauer 2002) . The Texas Medication Algorithm Project (TMAP) examined the effects of using medication algorithms for schizophrenia, bipolar disorder, and major depressive disorder under conditions in which implementation of the algorithms was aided by provision of a clinical coordinator (CC) to work with physicians and to administer an educational program to patients and their families. The rationale and general outline of the project have been described previously (Gilbert et al. 1998; . The results presented here are the clinical outcomes for patients with schizophrenia over their first 12 months of treatment.
As detailed below (Methods) and elsewhere , TMAP consisted of a package of interventions that included treatment manuals, CCs, expert consultations through conference calls and site visits, and an extensive multistep patient and family education program (Toprac et al. 2000) . The principal analyses are of the effects of this package of interventions compared with treatment as usual (TAU). The duration of patient enrollment was 13 months. Following enrollment, patients participated in the study for 1 to 2 years, depending on when they enrolled. Because all patients potentially had at least 1 year of participation, the analyses focus on the clinical outcomes over the first 12 months following study entry.
In keeping with usual clinical practice, the main focus of algorithm-guided treatment (ALGO) was on Send reprint requests to Dr. A.L. Miller, Department of Psychiatry, MS 7792, University of Texas Health Science Center at San Antionio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900; e-mail: millera@uth-scsa.edu. symptom improvement. For schizophrenia, both positive and negative symptoms were clinically monitored, because improvement in these symptoms with antipsychotic treatment has been most extensively evaluated . Because impairments in cognitive functioning have been shown to be very strongly related to poor adaptation and role functioning in schizophrenia (Green 1996; Velligan et al. 1997) , we also included a brief battery of cognitive function tests.
Participating clinicians were given specific guidance and prompting with regard to medication use and assessment of symptoms and side effects at each clinic visit. They were, however, free to exercise their own clinical judgment and to deviate from algorithm recommendations if they felt that this was clinically indicated. The results presented here, therefore, reflect the effects of ALGO as it was actually implemented.
The medication algorithms developed for the treatment of schizophrenia and related disorders have been detailed elsewhere . They were based in large part on the American Psychiatric Association guidelines (APA 1997) and the first version of the Expert Consensus Guidelines (Frances et al. 1996) for schizophrenia. The antipsychotic algorithm was subsequently modified to incorporate recommendations for use of olanzapine and quetiapine when these antipsychotics were approved by the U.S. Food and Drug Administration. Because evidence was, and still is, lacking on response rates to trials of subsequent atypical antipsychotics after one has failed, the antipsychotic algorithm gave clinicians the option of trying each agent or skipping ahead to clozapine, depending on clinical judgment.
Methods
Study Design. This multisite trial compared ALGO with TAU for schizophrenia and schizoaffective disorder (excluding bipolar type). Physicians in four clinics used ALGO, while physicians in eight matched clinics used TAU. Four TAU clinics used no algorithms for any disorder and had no augmentation of their clinical staff. The other four TAU clinics used algorithms and had CCs to assist in administering the intervention packages for depression or bipolar disorder but not schizophrenia (TAU-AC, treatment as usual in an algorithm clinic). Study assignment to ALGO or TAU was by clinic rather than by physician or patient. Study assignment (e.g., randomization) by patient rather than by clinic would have required physicians to follow ALGO with some patients but not others with the same diagnosis. Assignment by physician would have required some physicians in the same clinic to use ALGO while others would deliver TAU. This method would require that physicians avoid sharing experiences with one another and not cover for each other to avoid contaminating TAU with ALGO ("water cooler" effect). A limited number of clinics were available for study participation, and to reflect the geographic and demographic diversity of Texas, the clinics were chosen to be diverse by design.
Given these factors, study cell assignments by clinic were matched rather than randomized. When possible, clinics were matched in order to have an ALGO clinic and a TAU clinic for the same disorder within the same local mental health authority. This was often not possible for rural authorities with limited numbers of clinics. In such cases, we attempted to match an ALGO clinic with a similar-type TAU clinic (e.g., rural ALGO with rural TAU). Finally, we tried to match a given ALGO clinic with a TAU clinic that was similar in ethnic composition.
The primary test of the effects of ALGO versus TAU was the comparison between the ALGO group and the TAU group seen in clinics in which no algorithms were being used. The TAU-AC group provides an indication of the possible impact of using an algorithm for one disorder on TAU for another disorder.
The study was conducted in accordance with international guidelines for good clinical practice and the Declaration of Helsinki. It was approved by the Institutional Review Boards of the University of Texas Southwestern Medical Center at Dallas and the University of Texas at Austin. After entry into the study, symptoms, function, quality of life, side effect severity and burden, and utilization of health care and other public and private services were evaluated at baseline and quarterly for at least a 12-month period in all available participants.
Patient participants gave written informed consent for the research ratings and for access to their medical and administrative records. For ALGO, patient consent was obtained at the time of the decision to change antipsychotic medication. The medication decisions were not contingent upon agreement to participate in the study. Potential TAU patients were identified as described below. Individuals meeting TAU eligibility criteria were approached by a research coordinator to obtain written informed consent to the research procedures. Clinic personnel were not asked to give informed consent. All were voluntary participants in the project.
ALGO Intervention. The primary goal of the ALGO intervention was to optimize pharmacotherapy and improve clinical outcomes. Multiple tools were provided for the physicians and the treatment team to enhance their adherence to the algorithm. The primary aim of pharma-cotherapy was remission of symptoms. Each physician implemented the intervention in close collaboration with a CC, who assisted the physician by obtaining symptom and side effect measures at each visit, by providing patient and family education, and by reminding the physicians of the ALGO guidelines.
The CCs were mental health professionals (nurses, social workers, psychologists, counselors) with at least 2 years of experience. They and the ALGO physicians received 2 days of training on the ALGO interventions at the outset of the project, and ongoing consultations from investigators (A.L.M., Jo.C, and M.L.C.) and the coordinator (Ju.C). Additionally, the CCs were trained on the brief rating scales of positive and negative symptoms initially, with quarterly retraining on standardized tapes.
The antipsychotic algorithm and algorithms for side effects and associated symptoms have been described elsewhere . Figure 1 shows the antipsychotic algorithm used during the study. A clinical procedures manual was the basis for training and ongoing guidance of the physicians and CCs. The manual contained specific recommendations for monitoring symptoms and side effect burden to inform medication decisions at clinic visits. Critical decision points were described in the manual for each medication step in order to define recommended minimum and maximum trial lengths. The manuals included recommended dose ranges and criteria for adequacy of treatment of positive and negative symptoms. Positive and negative symptoms were assessed at each clinic visit in ALGO with brief anchored rating scales using items taken from the Brief Psychiatric Rating Scale (BPRS; Ventura et al. 1993) or derived from the Scale for the Assessment of Negative Symptoms (SANS; Andreasen 1982) and the Negative Symptom Assessment (Alphs et al. 1989) . The response criteria are discussed in Miller et al. (1999) . The goal was to achieve a virtual absence of positive symptoms and, on average, no greater than mild negative symptoms. If these goals were not achieved after a medication trial of reasonable dose and duration, a medication change, based on the sequence in the algorithm, was recommended. In addition, ALGO patients were evaluated for overall side effect burden, core symptom severity, associated symptom severity, and level of functioning by the CC and physician before a decision was made to maintain or change the medication regimen at each clinic visit.
Each ALGO patient also received a multistep education program that provided information about the disease and its treatment (Toprac et al. 2000) . There was no comparable program for TAU patients. The patient education package encouraged patient participation in treatment decisions and treatment adherence. ALGO patients had an average of 4.9 visits (range 0-18) at which they received elements of the psychoeducation program. The basic educational materials were usually covered in the first three to six visits. Subsequently, patients had the option of participating in educational group discussions about their illness and its treatment.
Patient Selection. Male and female outpatients 18 years or older with a clinical diagnosis, by their treating physicians, of schizophrenia or schizoaffective disorder (unless specifically of the bipolar subtype) were included in the study in either the ALGO group or the TAU group based on their clinic assignments. Patients with clinical diagnoses of schizoaffective disorder, bipolar type, were excluded, based on the likelihood that their treatment would include long-term use of mood stabilizers and be more like that recommended in the bipolar algorithm (Suppesetal. 2001) .
Patients entered the ALGO group if their treating physician decided that an antipsychotic medication change was warranted because of lack of efficacy or because of side effects. Initially, TAU patients were to be selected for inclusion in the same manner as ALGO patients; that is, those patients with a diagnosis of schizophrenia who had a change in antipsychotic medication by their physician were eligible for enrollment in the study. However, it soon became apparent that it was uncommon for TAU patients to have a change in their antipsychotic medication and that an additional method would need to be used to define TAU study eligibility if we were to meet enrollment goals for the TAU group. Therefore, TAU patients were also recruited in an additional manner. If a TAU patient's most recent routine clinic 24-item Brief Psychiatric Rating Scale (BPRS 24 ) score was greater than the median for that mental health center, then the patient was eligible for screening for the study. An alphabetical list of patients meeting this criterion during the prior 6 months was given to the research coordinators, who then contacted patients on the list, starting with those seen more recently. If the patient was willing to be evaluated for the study, the research coordinator did a screening BPRS 24 -If the patient's score on this BPRS was higher than one standard deviation (SD) below the mean for the ALGO group, then the patient was eligible for entry into the TAU group. Only those individuals meeting these criteria and providing written informed consent were entered into the TAU group.
There were minimal exclusion criteria for study entry. Patients were excluded if they were unable or unwilling to give voluntary informed consent to the research evaluations, or if they had gross intoxication due to substance abuse at the initial visit. They were not, however, excluded on the basis of a history of substance abuse or dependence. Study Procedures. Study participants provided baseline demographic and medical history. They underwent a complete evaluation at the baseline visit with a research coordinator. The evaluation battery included symptom testing with the 24-item BPRS (Ventura et al. 1993) , the Scale for the Assessment of Negative Symptoms (SANS; Andreasen 1982), and the Calgary Depression Scale (Addington et al. 1993) ; function testing with the Short Form Health Survey (SF-12) mental and physical (Ware et al. 1996) ; and cognitive testing with Trails A and B, Verbal Fluency (categories and letters), and the Hopkins Verbal Learning Test (Reitan 1955 (Reitan , 1958 Lezak 1995; Benedict et al. 1998; Cadle et al. 2002) . These assessments were repeated quarterly for at least 12 months, except for the cognitive tests, which were administered at baseline, 3 months, and 9 months.
Subjects were also asked about the burden of side effects from medication during the past month that "bothered or interfered with daily functioning." Respondents were considered to have no significant side effects if they reported "no side effects" or "only mild side effects, not really significant," and to have significant side effects when they reported that side effects "bothered me, but could tolerate them," "really bothered me, I either need to change my medication or take something for the side effects," or "were so severe I had to be hospitalized."
Demographic information was obtained from a patient questionnaire administered during the face-to-face baseline interview. Alcohol use and drug use were assessed quarterly using the Drug Abuse Screening Test (Skinner 1982 ) (> 5 indicates drug abuse) and the Michigan Alcoholism Screening Test (Selzer 1971 ) (S 5 indicates alcohol abuse). The Patient Perception of Benefits is a 10-item self-report developed for this study, ranging from 10 (belief) to 50 (disbelief) that the patient will see improved functioning if he or she gets needed care.
Research Assessments. The research assessments (see Study Procedures) were conducted over a maximum period of 18 months. Because the enrollment period was 13 months and the followup period was 12 months, all patients had the opportunity to participate for 12 months, whereas only earlier enrollees had the opportunity to participate for longer periods. Because the number of participants fell markedly beyond 12 months, only results from the first 12 months are reported here, although data from beyond 12 months, when available, were used in the statistical modeling procedures. The assessors were initially trained in each of the assessments and had quarterly retraining on the structured clinical interviews. The assessors contacted and assessed ALGO and TAU patients independently of the patients' clinical providers.
Outcomes. The primary research outcome measure was the 18-item BPRS (Overall and Gorham 1962) , extracted from the 24-item BPRS. Secondary symptom measures included the SANS (Andreasen 1982) and the Calgary Depression Scale (Addington et al. 1993 ). Tests of cognitive functioning included Trails A and B (Reitan 1955 (Reitan , 1958 , Verbal Fluency (categories and letters) (Lezak 1995) , and the Hopkins Verbal Learning Test (Benedict et al. 1998) . Functional outcomes were measured with the SF-12 (Ware et al. 1996) . The population for the analysis of efficacy included all patients who were enrolled and had complete 18-item BPRS data on at least one postbaseline quarterly assessment.
Adherence Variables. Charts were reviewed and data extracted for medications prescribed at each visit. These data were used to estimate frequencies and doses of antipsychotic medications used. The number of patients in the ALGO or TAU group who were prescribed the antipsychotic at any time during the study period was divided by the number in the group to calculate frequencies of use. Average doses were calculated using the highest dose prescribed during the study. Because ALGO patients had more antipsychotic medication changes (see below), their total frequencies of receiving different antipsychotics are higher than the TAU group's.
Antipsychotic medication changes were part of the standard documentation of ALGO treatment. TAU antipsychotic medication changes were inferred from the chart recording of a prescription for an antipsychotic not previously noted for that patient during the quarter.
Duration of availability of medications prescribed at a visit was based upon the following data (in decreasing order of preference): actual number of pills if chart note indicated number of pills, actual number of days if chart note indicated number of days, or days until next clinic visit if a clinic appointment was scheduled; if there was no information, then 30 days was assumed. Because patients acquired their medications from multiple sources (Medicaid, local center pharmacy contracts, patient assistance programs, and samples), there was no possibility of using pharmacy medication fill data to look at actual medication possession. Thus, active orders were used as a marker of potential medication possession.
Statistical Analyses. Tests for differences between groups were based on 2-tailed tests with equal variance not assumed for continuous measures (based on Levene's test), chi-squares for discrete values, and chi-squares with continuity corrections for dichotomous measures.
As detailed elsewhere , hierarchical linear models (HLMs) were adapted to assess the impact of ALGO on patient outcomes based on declining effects analyses developed for this study by Kashner et al. (2003) . This approach allowed investigators to compare separately those changes that occurred initially (within 3 months) and over time (12 months). Estimates for the initial change in outcomes between baseline and the first 3-month followup were computed separately for ALGO and for TAU. Following the initial change, we estimated changes in outcomes over the subsequent 9 months (i.e., months 3-12). Differences between ALGO and TAU were computed for initial changes (initial effects) and growth rates (growth-rate effects).
Differences between ALGO and TAU in the value of the outcome measure assessed at baseline would factorload onto any group differences observed over time. Thus, patient outcome measures were determined as change scores from baseline values.
Because groups differed on a number of variables that could potentially affect outcomes, statistical comparisons were done using adjusted values. The basis and rationale for the methodology are discussed in detail in and . In brief, raw data were adjusted using covariates known to affect health outcomes, selecting items that were significantly associated with the primary outcome variable (BPRS lg ) in this study. For each domain, covariates included the most significant covariate that was linearly associated with outcomes based on a univariate model. Additional variables were included provided they were statistically significant at a 0.05 alpha level. Thus, the covariate domains (items assessing them) were need (baseline symptom score, age), predisposition to seek care (years of education, patient perception of benefits), enabling factors (family size, disposable income), and demographic items (ethnicity, race, sex).
Final estimates were insensitive to model respecification, because including or excluding other covariates in the presence of the selected covariates did not change the results of ALGO/TAU outcome comparisons. Moreover, high model reliability (> 75%), final HLM estimates that were very similar to their least squares starting estimates, and our use of robust standard errors, gave investigators confidence that reported estimates were relatively free of misspecification error in either the estimated effects or the respective standard errors upon which significance tests were based.
Growth-rate effects were used to determine whether initial effects increased, remained constant, or declined during followup. Typical HLM analyses utilize a growth effects model that is powered to detect growth in differences between patients who receive a treatment and get better, and those in a control condition who either get worse, do not get better, or do not improve as much as those in the intervention group. Initial examination of our data, however, indicated an initial effect in favor of the ALGO group and, at least with some analyses, a tendency for a declining effect over time (i.e., the control group begins to "catch up" with the intervention group over time). This declining effect over time after an initial effect may actually be expected in service intervention studies for chronic disease states where differences between intervention and control groups over time may be complex. Growth effect models do not consider initial effects separately from further growth, and they collapse differences between treatment groups and controls over time into a single parameter. Thus, they are not powered to detect a declining effect. The declining effects model developed for analysis of these data adds an additional parameter in that it examines the initial effect and then the continuing effect over time after the initial effect. Thus, it has greater power to detect a declining effect after an initial effect or no change after an initial effect and is a superior analytic model to use for these types of data .
Specifically, time since baseline was entered as a continuous variable in a time level I and patient level II HLM. Dependent variables were patient outcomes measured at 3-month intervals and computed as change scores by subtracting each followup assessment from the respective value determined at baseline. For each treatment group (ALGO and TAU), the initial change and growth rates were computed, respectively, by the regression constant and time coefficient, while initial and growth-rate effects (ALGO-TAU) were computed by group indicator and time X group-indicator interaction. The group-indicator variable assumes the value of 1 for ALGO patients and 0 for TAU patients.
For Trails A and B data, values were transformed to natural logarithms to normalize distributions. To group the cognitive test results into a summary measure for each patient, each score was converted into a z score, and the z scores were summed for each patient at each time point. Summary scores of cognition, using z scores, have proven to be sensitive measures of drug effects in schizophrenia and provide a measure of the overall magnitude of change (Purdon et al. 2000; Bilder et al. 2002; Green et al. 2002) .
Results
A total of 512 patients met the criteria for the study and signed informed consent; of these, 9 did not complete baseline, 29 failed to report for any followup visit, and 9 had a followup visit but did not complete at least one primary symptom measure (BPRS ]g ). The remaining 465 evaluable patients completed the primary symptom measure at baseline and at least one followup visit, including 165 patients from four ALGO clinics, 144 patients from four TAU clinics using no algorithms for any of the three disorders, and 156 patients seen in TAU clinics using an algorithm for another disorder. The ALGO group and the TAU group seen in clinics not using other algorithms constituted the primary analytic sample (n -309).
For the primary analytic sample, baseline BPRS 18 was lower for ALGO than for TAU patients (38.75 vs. 45.38 [SD = 10.71], A = -6.63, t = 5.31, df = 307, p < 0.001). With lower initial values in the ALGO group, regression to the mean bias would work against finding a favorable ALGO effect on outcome, and thus the analytic approach is conservative.
The HLM analyses of the primary analytic sample used all subjects with at least one postbaseline BPRS lg rating. The percentages of subjects meeting this criterion at 3, 6, 9, and 12 months were 100 percent, 95 percent, 91 percent, and 86 percent, respectively. Thus, retention of subjects in the study was excellent. Table 1 lists the demographic characteristics of the primary analytic sample (ALGO and TAU groups), as well as the group of TAU patients seen in a clinic in which clinicians were using algorithms for bipolar or major depressive disorder (TAU-AC). The groups did not differ significantly from one another on most variables. Most covariates (see list in legend to table 2) were not statistically significant predictors of change scores, and thus potential biases introduced by these factors are expected to be small. Initial BPRS 18 scores and Hispanic status were significant predictors of BPRS ]8 change scores. BPRS lg change scores dropped by an average across subsequent time points of ABPRS, g = -0.55 (standard error [SE] = 0.05, t = 12.28, df = 269, p < 0.001) for each BPRS, 8 P°' nt mat baseline symptom scores were above mean values, underscoring concerns for regression to the mean biases. Compared with Caucasians, BPRS 18 scores declined more in Hispanic patients, by an average across postbaseline time points of ABPRS 18 = -3.81 (SE= 1.08, t = 3.52, df= 269, p< 0.001). Table 2 presents unadjusted BPRS 18 scores for all three groups. Statistical analyses were done using adjusted values. Table 3 contains adjusted data on the main symptom measures. The initial change is the change in score over the first 3 months. The growth rate is the quarterly change in scores over the next 9 months. For the BPRS 18 , SANS, and Calgary Depression Scale, decreases in scores represent improved symptoms. For the SF-12 mental and physical, increases in scores indicate improvements in these patient self-reports. On the primary symptom outcome measure, the BPRS 18 both groups had significant decreases in scores over the first 3 months (table 3). The decline was significantly greater in the ALGO group compared with the TAU group. Over the subsequent 9 months, the TAU group had a further significant decline in symptoms, catching up with the ALGO group in terms of symptom improvement. These results are illustrated in figure 2 .
Negative symptoms, as measured by the SANS, declined significantly in both groups over the first 3 months, but the two groups did not differ significantly from one another (table 3) .
The ALGO and TAU groups did not differ significantly in initial or subsequent changes in scores on the Calgary Depression Scale (table 3) . Depressive symptoms did improve significantly in both groups during the first 3 months.
There were no overall group differences on the SF-12 mental or physical (table 3) .
Unadjusted cognitive test performance scores for all groups are shown in table 4, with results at baseline, 3 months, and 9 months. To put all scores on comparable dimensions, we converted them to z scores and computed the z-score differences. Table 5 shows these results for the primary comparison between ALGO and TAU groups. During the first quarter, the ALGO group had significantly greater improvements than the TAU group in scores on Trails A and Verbal Fluency (letters). By the end of the third quarter, Verbal Fluency (categories) was also significantly more improved in the ALGO group than in the TAU group. Results on the combined tests, expressed as z scores, were significantly more improved in the ALGO group at both 3 and 9 months after study entry. The combined z scores are shown in figure 3 .
The TAU-AC group allowed secondary comparisons with ALGO that could be compared with the results of ALGO comparisons with TAU. Secondary symptom comparisons of the ALGO group with the TAU-AC group are summarized in table 6. The greater initial decline in BPRS )8 score in the ALGO group was not found in this comparison, although significant initial effects favoring improvement in the ALGO group were noted on the SF-12 mental and physical.
The greater improvements in cognitive function in the ALGO group, found in the primary comparison, were replicated in the comparison with the TAU-AC group. The z scores and differences between groups are shown in table 7.
ALGO and TAU groups differed with respect to physician behaviors that reflected the impact of ALGO implementation. ALGO patients had more medication changes and more medication visits, especially in the first quarter (table 8). The frequency of using different antipsychotics varied between groups and across time (table 9) . Average doses were similar in most instances, with higher doses of olanzapine in the ALGO group being the only significant difference. (Skinner 1982) . 6 Patient Perception of Benefits is a 10-item questionnaire ranging in score from 10 to 50, where 10 indicates that patients strongly agree and 50 indicates that patients strongly disagree that they will obtain improved functioning if they get the care they need. Note.-ALGO » algorithm-guided treatment; BPRS 18 = 18-item Brief Psychiatric Rating Scale; SD -standard deviation; TAU = treatment as usual; TAU-AC «treatment as usual in an algorithm clinic. 1 Values shown are unadjusted BPRS )8 scores and SDs for each subject group at the times noted. For analytic purposes, scores were adjusted for baseline patient characteristics as described in Methods. For all patients, baseline SANS means and standard deviations were 14.06 ± 4.86, n = 164 (ALGO), and 13.03 ± 5.05, n = 142 (TAU), for a mean difference of -1.03 ± 0.57 (t = 1.81, df** 294, p = 0.071, equal variances not assumed, 2-tailed test), suggesting a potential regression to the mean bias that works /nfaiw of finding an ALGO effect of lower SANS followup scores.
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For all patients, baseline Calgary Depression Scale means and standard deviations were 6.66 ± 5.00, n = 165 (ALGO), and 7.88 ± 4.95, n -141 (TAU), for a mean difference of -1.22 ± 0.57 ((= 2.14, df" 304, p = 0.033, equal variances assumed, 2-tailed test), suggesting a potential regression to the mean bias that works against finding an ALGO effect of lower Calgary Depression Scale followup scores.
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For all patients, baseline SF-12 mental means and standard deviations were 39.67 ± 12.09, n = 161 (ALGO), and 38.82 ± 9.41, n = 138 (TAU), for a mean difference of -0.85 ± 1.25 (f = 0.68, o¥= 294, p = 0.50, equal variances not assumed, 2-tailed test), suggesting a negligible regression to the mean bias that works against finding an ALGO effect of higher SF-12 mental followup scores.
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For all patients, baseline SF-12 physical means and standard deviations were 45.02 ± 11.40, n = 161 (ALGO), and 43.54 ± 10.82, n -138 (TAU), for a mean difference of 1.48 ± > 1.29 (f = 1.14, df= 296, p = 0.25, equal variances assumed, 2-tailed test), suggesting a negligible regression to the mean bias that works against finding an ALGO effect of higher !"" SF-12 physical followup scores. The likelihood of rinding documentation in the chart of an active order for an antipsychotic was 94 percent in the ALGO group and 51 percent in the TAU group. The low number in the TAU group does not necessarily mean that the patients were not taking an antipsychotic but does mean that half the time there was insufficient information in the chart to conclude or infer that patients had enough antipsychotic medication to last until the next clinic visit.
Discussion
The results indicate some advantages of ALGO compared with TAU in the treatment of schizophrenia and schizoaffective disorder, but the differences are not uniform across time or across outcome domain. This discussion will focus first on the primary comparisons between the ALGO intervention and TAU in clinics not using any ALGO interventions. The possible implications of the results in the secondary TAU group, those seen in clinics using ALGO for another disorder, will then be discussed.
The magnitude of the symptom changes found in this study of a population of typical public mental health patients was not large, in either the ALGO condition or the TAU condition. There are surprisingly few studies of long-term symptom outcomes in schizophrenia outpatients with which our results can be compared. In recent years, since the advent of the atypical antipsychotics, most long-term studies using active comparators have been extensions of inpatient acute intervention studies. The pool of patients recruited into these extension studies is quite different from the pool of outpatients in our study, as the former is selected for those already known to have benefited from the inpatient treatment.
In a large multinational study comparing olanzapine with haloperidol treatment of outpatients with schizophrenia, Tollefson et al. (1997) found that observed case decreases in BPRS 18 scores at 6 weeks were 15.0 and 12.7 points, respectively, beginning with mean baseline values of 51 to 52. The differences were statistically significant in a repeated measures analysis. The dropout rates were 30 to 50 percent. In our study, the decreases at 3 months were 5.65 and 3.36 in the ALGO and TAU groups, respectively, beginning with adjusted mean values of 42 (table 3). The dropout rates were less than 10 percent. Thus, the overall improvements were greater in the olanzapine study, but this difference may be partly attributable to different dropout rates and more symptomatic patients at baseline. The difference between the active treatment groups, 2.3 BPRS scale points, was identical in the two studies.
The magnitude of symptom changes observed in the BPRS 18 in the current study can also be viewed in comparison with another longer term outpatient study. A recently published study of maintenance outpatient treatment for schizophrenia with risperidone or haloperidol found that the rate of relapse was lower with risperidone (Csernansky et al. 2002) . Using endpoint values, scores on the Positive and Negative Syndrome Scale (Kay et al. 1987) decreased, on average, 3.1 points in the risperidone group and rose, on average, 2.8 points in the haloperidol group, starting with baseline values of 65 and 67, respec- Note.-ALGO = algorithm-guided treatment; TAU -treatment as usual; TAU-AC •= treatment as usual in an algorithm clinic. 1 Values shown are mean (standard deviation) for each test and group at the times noted. For analytic purposes, scores were adjusted for baseline patient characteristics as described in Methods.
tively. In our study, the 12-month decreases in BPRS 18 scores were 5.3 and 4.9 points in the ALGO and TAU groups, respectively. Because of very different entry criteria and rates of dropout, and because early endpoint values are handled differently in our HLM analyses than in last observation carried forward (endpoint) analyses, the results of the two studies are not directly comparable. Nonetheless, both studies indicate that, over the course of a year, overall reductions in symptomatology are modest, whether patients are followed in research centers (as in the Csernansky et al. [2002] study) or in public mental health clinics (as in this study). Much more dramatic effects might have been found by enrolling acutely exacerbated inpatients. This was not done because our preliminary studies found that influencing inpatient medication management and coordinating the transition of medication use from inpatient to outpatient status was extraordinarily difficult in our system. Figure 2 shows that from 3 to 12 months the TAU patients had further significant improvements in BPRS lg Note.-ALGO -algorithm-guided treatment; TAU = treatment as usual.
scores and caught up with the ALGO patients. The fact that ALGO patients did not evidence further improvement has multiple possible explanations, some of which may be able to be evaluated with further analyses. Because the ALGO approach encouraged the treatment team to seek a high level of symptom response, particularly in terms of reduction in positive symptoms, the lack of a better response in this condition over the longer term could mean that maximum benefit had already been achieved (ceiling effect) in this seriously and chronically ill patient population, or it could signify that the ALGO clinicians were sufficiently satisfied with the initial responses that they chose not to strive for further symptom reduction with subsequent medication changes. Unidentified factors in the service delivery system could have made it difficult for the physicians to deliver more assertive treatment. Further analyses of ALGO physician adherence to the algorithm's criteria for adequacy of response may help resolve these questions. Analyses of the impact of adherence to the intervention package are, unfortunately, not straightforward. It is much easier to adhere to guidance with respect to dosing, visit frequency, switching medications, and so on with cooperative and responsive patients than with uncooperative or nonresponsive patients. Therefore, a strong relationship of adherence to the intervention package with good outcomes can be the result of good patient outcomes making adherence to the recommendations easier, rather than good adherence making patient outcomes better.
The results presented in tables 8 and 9 do indicate that ALGO physicians saw their patients more frequently for medication visits, made more antipsychotic medication changes, and had different prescribing profiles, as compared with their TAU counterparts. Moreover, ALGO physicians were much more likely to have active medication orders in their charts. Thus, ALGO implementation did affect important physician behaviors.
The presence of CCs in the clinics to assist physicians in caring for ALGO patients undoubtedly affected physicians' willingness to consider medication changes for patients with less severe symptoms or side effects. Thus, enrollment of patients in ALGO clinics was rapid, whereas the rate of medication changes in TAU clinics was so slow that it became clear that these physicians must be using different criteria for medication changes than physicians in ALGO clinics. The change in ALGO clinic culture was desirable, in terms of the goals of the intervention, but resulted in baseline differences between patient groups that could have confounded the comparisons between ALGO and TAU. If one disregards the TAU data and, instead, examines the data in tables 3 and 5 solely from the viewpoint of the impact of the intervention on ALGO patients, the picture that emerges is one of initial improvements in virtually all measures. These improvements were sustained over time in the symptom measures (table 3) and increased over time in the cognitive measures (table 5) . That is, the initial positive effects of the ALGO intervention did not dissipate, as might have been expected if they had resulted from short-term effects of a novel treatment.
There were no overall significant group differences in changes in negative symptoms (SANS), depressive symptoms (Calgary Depression Scale), or patient-rated mental and physical functioning . Both TAU and ALGO showed significant initial improvements in SANS and Calgary scores. The ALGO clinicians were encouraged to be alert to depressive symptoms and to treat them vigorously, but no specific criteria for treatment or for response were used. Given the high prevalence of depressive symptoms in patients with chronic schizophrenia (Sins 2000), it might have been useful to incorporate more specific recommendations for assessing and adequately treating depression in the ALGO procedures. Further analyses may help determine whether antidepressant medications were used similarly in the ALGO and TAU groups or were used more aggressively by the ALGO clinicians without achieving better results. In the case of negative symptoms, a brief four-item scale was administered by the CCs at each visit, to guide algorithm intervention. The response criterion for negative symptoms was not stringent, because of the uncertainty in the literature as to what is an achievable level of improvement. Clinicians were urged to use the scale results in the context of their own clinical judgments about the degree of impairment attributable to negative symptoms and the risks and benefits of med- I ication changes targeted at improving negative symptoms. The fact that there were greater improvements in overall cognitive performance in the ALGO group was especially interesting because of the growing evidence that cognitive deficits contribute substantially to the functional impairment characteristic of many patients with schizophrenia (Green 1996; Velligan et al. 1997) . A broader battery of tests administered at each quarter with the other outcome measures would have been desirable but was not feasible, because of resource limitations and the burden on patients of extended assessments. The Hopkins Verbal Learning Test was selected because of its ease of administration and its availability in multiple equivalent forms. However, its sensitivity to change in patients with schizophrenia has not been well demonstrated. This lack of sensitivity could have contributed to the lack of group differences on this measure in this study.
The time course of improvement was not the same with each cognitive test, although the overall trend was for greater improvements in the ALGO group across time (figure 3). Time to perform the Trails A test decreased most in the ALGO compared with the TAU group during the initial 3 months. Group differences in improvements on the Verbal Fluency tests (categories, letters) were, on the other hand, greater over the 9-month period than over the initial 3 months. This finding suggests a more enduring effect of ALGO on this complex measure of initiation, recall, and retrieval than was found in the clinical symptom measures.
Because ALGO was a multifaceted intervention, targeted mainly toward medication management and symptom improvement, it is difficult to ascribe the apparent effects on cognition to any particular aspect of the intervention. The fact that the effect occurred in both group comparisons is somewhat reassuring as to its validity, but we recognize the need for confirmation of the finding in future studies, as well as the importance of experimental designs that will permit identification of elements of the intervention that influence cognitive test performance.
Regarding the secondary comparisons between the ALGO group and the TAU-AC group, results were somewhat different than those found in the primary comparisons, with regard to symptom measures. Significantly greater improvement in BPRS scores in the ALGO group during the first 3 months was not found, but the SF-12 mental and physical did improve more in the ALGO group during this time period (tables 3 and 6). These differences are not easily explained. Given the relatively small magnitude of the group differences on symptom measures, however, it may not be too surprising that the symptom findings were somewhat unstable across comparison groups. The cognitive function test results showed a more consistent pattern. All groups improved over time, with greater improvements being sustained in the ALGO compared with both of the TAU groups (tables 5 and 7). These findings of greater improvement in cognitive test scores in the ALGO group are of great interest but should not be overinterpreted. Further analyses will test whether there were functional consequences in terms of resource utilization and need for unscheduled interventions.
One might argue that there was an "algorithm culture" effect that encouraged clinicians using ALGO interventions to be more aggressive in treating residual symptoms. This could account for the greater initial improvement in the BPRS in TAU-AC patients than in TAU patients. This conclusion is highly tentative, but it would be interesting to design future studies that specifically address the "halo effect" of changing the management of one disorder on management of other disorders treated by the same clinicians.
This study enrolled outpatients in public mental health clinics. It was not possible to blind clinicians or raters to the group assignments. Moreover, the ALGO clinicians were free to treat each patient as they saw fit, even though they were coached to follow the algorithm manual. In addition, all patients in the ALGO group were "medication failures" (with regard to efficacy or side effects) based on individual physician judgment and had a primary medication change at study entry, whereas patients in the TAU group could be enrolled on the basis of either having a primary medication change or having a high level of symptomatology. Thus, our findings reveal outcomes assessed by nonblinded but independent raters and reflect the actual (i.e., less than perfect) levels of algorithm implementation achieved in participating clinics. It is possible that better results might have been found if it had been possible to ensure that clinicians always followed the algorithm's recommendations. It is also conceivable that rater bias in favor of ALGO could have influenced the results, although the fact that the research raters were not part of the clinical treatment teams makes this less of a concern, as does the observation that group differences in outcomes varied across outcome domains.
Because patients in the ALGO and TAU groups were not randomly assigned or matched and were chosen on the basis of somewhat different inclusion criteria, group differences could have affected the results. The statistical procedures attempted to control for group differences by controlling for selected covariates, including need for services, predisposing factors, enabling factors, and other demographic variables. While caution is recommended when statistical controls are used instead of random assignment, the changes between unadjusted and adjusted estimates of initial and growth effects were small, indicating that the declining effects model applied to these data is robust.
Last, we wish to reemphasize that the results presented here are for ALGO and TAU as actually implemented in these two groups of patients. The results reflect what was achieved with relatively modest additional resources in an underresourced system, using guidelines that clinicians likely implemented to varying degrees. Note.-ALGO -algorithm-guided treatment; BPRS 18 = 18-item Brief Psychiatric Rating Scale; SD » standard deviation; TAU = treatment as usual. 1 Frequencies (%) of prescriptions for antipsychotics after the initial visit, for all antipsychotics where the sum of ALGO + TAU was 210% during the first quarter. The percentage receiving medication was analyzed using a logistic regression. Treatment group was used as a predictor of use/nonuse of medication along with baseline BPRS 18 , age, family size, disposable income, years of education, Patient Perception of Benefits, gender, African-American status, and Hispanic status. The doses are the average highest dose of the antipsychotic during the study. Patients who did not receive at least one postbaseiine dose of the medication are not included in the dose analysis for that medication. An analysis of covariance was used for dose with the same covariates listed above. 
